Treatment of breast cancer cells with a combination of de-methylating agents and histone deacetylase (HDAC) inhibitors fully restored ERβ expression (109), and recently a therapeutic approach with combinations of HDAC inhibitors and SERMs (hybrid drugs termed SERMostats) is being investigated in breast cancer (110). Here, HDAC9 is linked to breast cancer.